Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Singapore-based biotech company S*Bio has expanded its proprietary pipeline with its third development candidate, SB1317, a novel orally available small molecule compound targeted for the treatment of acute leukemias.
Subscribe to our email newsletter
According to the company, SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. By inhibiting both Flt3 and CDK kinases, SB1317 is said to be positioned as a first-in-class compound to treat relapsed and refractory acute leukemias. SB1317 has already entered preclinical development.
Jan-Anders Karlsson, CEO of S*Bio, said: “With its ideal profile for treating relapsed and refractory AML and ALL, SB1317 provides an opportunity for S*Bio to expand its portfolio of new targeted therapies for hematological disorders.”